Maurizio Scaltriti

Maurizio Scaltriti

UNVERIFIED PROFILE

Are you Maurizio Scaltriti?   Register this Author

Register author
Maurizio Scaltriti

Maurizio Scaltriti

Publications by authors named "Maurizio Scaltriti"

Are you Maurizio Scaltriti?   Register this Author

97Publications

3433Reads

50Profile Views

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System.

J Vis Exp 2020 Jan 9(155). Epub 2020 Jan 9.

The Shraga Segal Department of Microbiology, Immunology and Genetics, Ben-Gurion University of the Negev; Faculty of Health Sciences, Ben-Gurion University of the Negev;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/60410DOI Listing
January 2020

Prevalence and role of HER2 mutations in cancer.

Pharmacol Ther 2019 07 2;199:188-196. Epub 2019 Apr 2.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01637258193005
Publisher Site
http://dx.doi.org/10.1016/j.pharmthera.2019.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571037PMC
July 2019

PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.

Cell Rep 2019 04;27(1):294-306.e5

Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Research & Development Oncology, AstraZeneca Pharmaceuticals, Gaithersburg, MD 20878, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247193029
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2019.02.111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503687PMC
April 2019

NTRK fusion-positive cancers and TRK inhibitor therapy.

Nat Rev Clin Oncol 2018 12;15(12):731-747

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0113-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419506PMC
December 2018

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Cancer Cell 2018 12;34(6):893-905.e8

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Breast Medicine Service, Department of Medicine, MSKCC, New York, NY 10065, USA; Weill-Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183052
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294301PMC
December 2018

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

J Clin Oncol 2018 08 10;36(24):2532-2537. Epub 2018 Jul 10.

Bob T. Li, Ronglai Shen, Darren Buonocore, Zachary T. Olah, Ai Ni, Michelle S. Ginsberg, Gary A. Ulaner, Michael Offin, Daniel Feldman, Helen H. Won, Edyta B. Brzostowski, Gregory J. Riely, David B. Solit, David M. Hyman, Alexander Drilon, Charles M. Rudin, Michael F. Berger, Jose Baselga, Maurizio Scaltriti, Maria E. Arcila, and Mark G. Kris, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Bob T. Li, Nick Pavlakis, and Stephen Clarke, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and Todd Hembrough, Fabiola Cecchi, and Sarit Schwartz, NantOmics, Rockville, MD.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.77.9777
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.77.9777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366814PMC
August 2018

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.

J Cell Biochem 2018 06 1;119(6):4287-4292. Epub 2018 Mar 1.

Department of Medical, Surgical and Health Sciences, Teaching Hospital of Cattinara, University of Trieste, Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.26687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995110PMC
June 2018

Coamplification of protects -amplified breast cancers from targeted therapy.

Proc Natl Acad Sci U S A 2018 03 23;115(11):E2594-E2603. Epub 2018 Feb 23.

Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1717820115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856537PMC
March 2018

A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer.

Cancer Converg 2017 29;1(1). Epub 2017 Dec 29.

1Department of Physics, The Pennsylvania State University, University Park, PA 16802-6300 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41236-017-0007-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876695PMC
December 2017

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.

Nat Commun 2017 07 11;8:15987. Epub 2017 Jul 11.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms15987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508201PMC
July 2017

The emerging role of serum/glucocorticoid-regulated kinases in cancer.

Cell Cycle 2017 01 16;16(1):5-6. Epub 2016 Sep 16.

a Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2016.1232071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270517PMC
January 2017

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

J Nucl Med 2016 09 14;57(9):1413-9. Epub 2016 Apr 14.

Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.169417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093919PMC
September 2016

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

Cancer Cell 2016 08 21;30(2):229-242. Epub 2016 Jul 21.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982440PMC
August 2016

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Mol Cell Oncol 2014 Jul-Sep;1(3):e963447. Epub 2014 Oct 29.

Human Oncology & Pathogenesis Program (HOPP); Memorial Sloan Kettering Cancer Center ; New York, NY USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/23723548.2014.963447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904898PMC
June 2016

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Sci Transl Med 2016 06;8(345):345ra87

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064151PMC
http://dx.doi.org/10.1126/scitranslmed.aaf7374DOI Listing
June 2016

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Clin Cancer Res 2016 Apr 20;22(8):2009-19. Epub 2015 Nov 20.

Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, New York. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870591PMC
April 2016

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.

Clin Cancer Res 2016 Mar 13;22(6):1313-7. Epub 2016 Jan 13.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, New York. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1458DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957976PMC
March 2016

Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas.

Proc Natl Acad Sci U S A 2016 Mar 29;113(11):3030-5. Epub 2016 Feb 29.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065; Howard Hughes Medical Institute, New York, NY 10065

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1523693113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801318PMC
March 2016

Somatic PIK3CA mutations as a driver of sporadic venous malformations.

Sci Transl Med 2016 Mar;8(332):332ra42

Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaf1164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962922PMC
March 2016

AKT signaling in ERBB2-amplified breast cancer.

Pharmacol Ther 2016 Feb 2;158:63-70. Epub 2015 Dec 2.

Memorial Sloan Kettering Cancer Center (MSKCC), Human Oncology and Pathogenesis Program (HOPP), NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2015.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747800PMC
February 2016

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Quantification of HER family receptors in breast cancer.

Breast Cancer Res 2015 Apr 9;17:53. Epub 2015 Apr 9.

Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0561-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389676PMC
April 2015

Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

Expert Opin Investig Drugs 2015 Mar 3;24(3):421-31. Epub 2015 Feb 3.

Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO) - Candiolo Cancer Center (IRCCs), Institute for Cancer Research and Treatment of Candiolo , Strada Provinciale 142, Km 3.95, CAP 10060, Candiolo, Turin , Italy +39 0119933958 ; +39 0119621525 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2015.1008132DOI Listing
March 2015

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

*Authors contributed equally to this work.Affiliations of authors: Preclinical Research (JLPP, BM, ME, RV, MZF, KP, VS, AP, JA) and Clinical Research Programs (PN, JC, ITR), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain (VP); Human Oncology and Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, NY (MS, JB); Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, Salamanca, Spain (AP); Lineberger Comprehensive Cancer Center, Chapel Hill, NC (CMP); Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain (JA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (JA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271027PMC
November 2014

Therapeutic antibodies in breast cancer.

Semin Oncol 2014 Oct 21;41(5):576-88. Epub 2014 Jul 21.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.07.002DOI Listing
October 2014

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Mol Oncol 2014 Feb 13;8(1):20-6. Epub 2013 Sep 13.

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2013.08.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528507PMC
February 2014

Biomarkers of drugs targeting HER-family signalling in cancer.

J Pathol 2014 Jan;232(2):219-29

Unit of Investigative Clinical Oncology (INCO) and Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str Provinciale, 142 10060, Candiolo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4269DOI Listing
January 2014

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer Discov 2013 Nov 15;3(11):1238-44. Epub 2013 Aug 15.

1Vall d'Hebron Institut d'Oncologia; 2Vall d'Hebron Institut de Recerca; 3Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 5Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0132DOI Listing
November 2013

PI3K pathway inhibitors: better not left alone.

Curr Pharm Des 2013 ;19(5):895-906

Monash Medical Centre, Southern Health, Melbourne, Australia 3165.

View Article

Download full-text PDF

Source
July 2013

Molecular pathways: targeting hsp90--who benefits and who does not.

Clin Cancer Res 2012 Sep 20;18(17):4508-13. Epub 2012 Jun 20.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2138DOI Listing
September 2012

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Clin Cancer Res 2012 May 8;18(9):2603-12. Epub 2012 Mar 8.

Department of Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology, Pg Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2750DOI Listing
May 2012

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Cancer Discov 2011 Aug 17;1(3):248-59. Epub 2011 Jun 17.

Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-11-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227125PMC
August 2011

Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.

Mol Oncol 2007 Sep;1(2):196-204

Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2007.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408886PMC
September 2007

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

J Natl Cancer Inst 2007 Apr;99(8):628-38

Medical Oncology Program, Medical Oncology Department, Vall d'Hebron University Hospital and Research Institute, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djk134DOI Listing
April 2007

Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment.

Regen Med 2007 Mar;2(2):193-202

Department of Biomedical Sciences and National Institute of Biostructures and Biosystems, University of Sassari, Sassari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/17460751.2.2.193DOI Listing
March 2007

The epidermal growth factor receptor pathway: a model for targeted therapy.

Clin Cancer Res 2006 Sep;12(18):5268-72

Medical Oncology Service, Vall d'Hebron University Hospital and Universidad Autónoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-05-1554DOI Listing
September 2006

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

EMBO J 2006 Jul 22;25(13):3234-44. Epub 2006 Jun 22.

Medical Oncology Research Program, Vall d'Hebron University Hospital Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.emboj.7601191DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500971PMC
July 2006

Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling.

Carcinogenesis 2006 May 28;27(5):1047-53. Epub 2005 Nov 28.

Dipartimento di Medicina Sperimentale, Plesso Biotecnologico Integrato, Universita' di Parma, Via Volturno 39-43100 Parma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgi287DOI Listing
May 2006

Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.

Cancer Res 2004 Oct;64(20):7412-9

Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-2077DOI Listing
October 2004

Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1.

Cancer Res 2004 Sep;64(17):6174-82

Unitat de Recerca Biomedica, Hospital Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-0920DOI Listing
September 2004

Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer.

Int J Cancer 2004 Jan;108(1):23-30

Dipartimento di Scienze Biomediche, Università di Modena e Reggio Emilia, Modena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11496DOI Listing
January 2004

Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study.

Cancer Res 2003 Jul;63(13):3469-72

Dipartimento di Medicina Sperimentale, Plesso Biotecnologico Integrato, Università di Parma, Via Volturno 39-43100 Parma, Italy.

View Article

Download full-text PDF

Source
July 2003